Cargando…
Managing anemia in lymphoma and multiple myeloma
Anemia is common in cancer, and lymphoproliferative disease is no exception. Erythropoiesis-stimulating agents (ESA) have been used for renal anemia since 1986, and considerably later in cancer anemia. The first studies were published around 1993, but the use of ESA did not become common in cancer a...
Autor principal: | Birgegård, Gunnar |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504072/ https://www.ncbi.nlm.nih.gov/pubmed/18728848 |
Ejemplares similares
-
Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY
por: Birgegård, Gunnar, et al.
Publicado: (2006) -
New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia
por: Banaszkiewicz, Małgorzata, et al.
Publicado: (2019) -
A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial
por: Birgegård, Gunnar, et al.
Publicado: (2016) -
Autoimmune hemolytic anemia and hyperglobulinemia leading to the diagnosis of multiple myeloma
por: Pacca, Rafael Lopes, et al.
Publicado: (2017) -
Regulatory Effect and Mechanism of Erythroblastic Island Macrophages on Anemia in Patients with Newly Diagnosed Multiple Myeloma
por: Huang, Hao, et al.
Publicado: (2023)